Discussion
Cerebral metastasis is a rare manifestation of recurrent endometrial carcinoma and occurs in 0.3 to 0.9% of patients with this disease. 2, 7 Brain metastasis is the result of hematogenic spread. Tumor cell and endothelium receptors, as well as the microenvironment in target organs such as the CNS, may be responsible for this kind of distant metastasis. 7 The potential for endometrial cancer to metastasize to the brain is highly variable and unpredictable. 7, 9 Although no uniform pattern of risk factors for this kind of dissemination exists, an accumulation of negative histopathological factors such as retroperitoneal nodes positive for the presence of cancer cells, 3, 9 deep myometrial invasion, 5 cervical tumor extension, 5 vascular invasion, 5 and a low degree of differentiation 2 has been reported in these patients. Our two patients were also found to have deep myometrial invasion, vascular space invasion, and Grade 3 tumors; one patient had pelvic lymph nodes positive for the presence of cancer cells ( Table 1) .
The median survival time for patients with endometrial cancer that has metastasized to the brain has been reported to be no longer than 2 months, with a range from 0.2 to 83 months. 2, 7, 10, 12 Two groups have reported long-term survival (82 and 83 months, respectively) in patients in whom a solitary brain metastasis developed 3 and 13 months, respectively, after primary diagnosis of endometrial cancer. Both patients underwent neurosurgical resection and brain radiotherapy. 2, 10 Cerebral metastasis as the primary manifestation of an occult endometrial cancer is rare. So far, only five such patients have been reported (Table 2) . One of these was lost to follow up shortly after diagnosis. 3 None of these patients was observed to survive longer than 38 months.
To our knowledge, this is the first report of long-term survival following multimodal therapy for a gynecological cancer in a patient who initially presented with brain metastasis. It may be speculated as to which single factor or combination of factors contributed most to the favorable outcome in the patient in Case 1. That patient had a solitary brain metastasis, underwent radiosurgery of the brain and aggressive intraabdominal and pelvic tumor debulking, and received doxorubicin-based chemotherapy. A single brain metastasis seems to be associated with a better prognosis than the presence of numerous lesions. 2 Single lesions are more amenable to neurosurgical resection. 2 Aggressive cytoreductive abdominal surgery has been found to improve the prognosis of patients with Stage IV endometrial cancer. 1, 4 In addition, doxorubicin and cyclophosphamide are among the most active cytotoxic agents prescribed for this disease. 11 In contrast with data from previous reports on long-term survival in patients with brain metastasis following the diagnosis of endometrial cancer, 2,10 our patient (Case 1) did not undergo radiation therapy of the brain.
Conclusions
This is the first report indicating that long-term survival beyond one decade may be achieved in a select group of patients in whom a solitary brain metastasis is identified prior to diagnosis of primary endometrial cancer. Thus, aggressive therapy appears warranted in these patients.
